About Us
Nubratori RX, started just after the enactment of the Drug Quality and Securities Act of 2013 by Congress. Nubratori RX spent its first four years in research and development, testing, and validating potential new products as requested by providers. 2017 brought the launch of Nubratori RX’s first production run. To date, Nubratori RX has produced closed to 250,000 units of products, and counting, with zero adverse reports. After emerging from the COVID-19 pandemic, Nubratori RX continues to serve patients, providers, and clinics.
Nubratori RX, under its FDA Registration for Outsourcing Facilities, compounds and manufactures sterile and non-sterile medications requested by providers for having a clinical significance to meet patient's needs over other commercially available products on the market.
If you are a hospital administrator, pharmacist, or physician and would like to find out more, please contact us.
Meet the Team
COO and Director of Regulatory Affairs
Gulshakar Khwaja
Pharm D/MS
BioScience Regulatory Affairs
VP of Quality Control and
Director of Operations
Jennifer Wilson
Chemistry BS / CPhT
Supervising Pharmacist Production Manager
Alma Karimian
Pharm D
Director of Research and
New Product Development
Shanen Khwaja
Pharm D
Director of Sterile Compounding
William Packer
Pharm D
Director of Quality Assurance
Jocelyn DeGuzman
Pharmacy Technician
Director of Licensing
Yazmin Mendoza
Director of Licensing
Samantha Kawakami
Administrative Assistant
Jessica Gutierres

381 Van Ness Ave Suite 1507, 1508 Torrance, CA 90501
